Compare BUDA & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUDA | LIXT |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | 39 | 3 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 107.6M |
| IPO Year | N/A | N/A |
| Metric | BUDA | LIXT |
|---|---|---|
| Price | $10.79 | $7.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 594.5K |
| Earning Date | 03-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $2.45 |
| 52 Week High | $12.00 | $8.38 |
| Indicator | BUDA | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 54.53 |
| Support Level | $8.21 | $6.21 |
| Resistance Level | N/A | $7.64 |
| Average True Range (ATR) | 0.82 | 0.84 |
| MACD | 0.26 | -0.05 |
| Stochastic Oscillator | 64.00 | 53.35 |
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.